tiprankstipranks
CytomX Therapeutics Inc (CH:6C1)
:6C1
Switzerland Market
6C1
CytomX Therapeutics
RESEARCH TOOLSreports

CytomX Therapeutics (6C1) Stock Forecast & Price Target

0 Followers
See the Price Targets and Ratings of:

6C1 Analyst Ratings

Strong Buy
5Ratings
Strong Buy
5 Buy
0 Hold
0 Sell
Based on 5 analysts giving stock ratings to
CytomX
Therapeutics
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

6C1 Stock 12 Month Forecast

Average Price Target

―
Based on 5 Wall Street analysts offering 12 month price targets for CytomX Therapeutics in the last 3 months. The average price target is CHF10.24 with a high forecast of CHF12.80 and a low forecast of CHF8.80. The average price target represents a ― change from the last price of ―.
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
Highest Price TargetCHF12.80Average Price TargetCHF10.24Lowest Price TargetCHF8.80
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
J.P. Morgan Analyst forecast on CH:6C1
Anupam Rama
J.P. Morgan
J.P. Morgan
CHF8.8
Buy
―
Reiterated
08/17/26
CytomX Therapeutics (CTMX) Gets a Buy from J.P. Morgan
Barclays Analyst forecast on CH:6C1
Etzer Darout
Barclays
Barclays
CHF12.8
Buy
―
Reiterated
08/07/26
Barclays Sticks to Their Buy Rating for CytomX Therapeutics (CTMX)
Guggenheim Analyst forecast on CH:6C1
Michael Schmidt
Guggenheim
Guggenheim
CHF12→CHF11.2
Buy
―
Reiterated
08/07/26
CytomX Therapeutics price target lowered to $14 from $15 at GuggenheimCytomX Therapeutics price target lowered to $14 from $15 at Guggenheim
Piper Sandler Analyst forecast on CH:6C1
Edward Tenthoff
Piper Sandler
Piper Sandler
CHF9.6
Buy
―
Reiterated
08/07/26
Analysts Offer Insights on Healthcare Companies: CytomX Therapeutics (NASDAQ: CTMX), Cytokinetics (NASDAQ: CYTK) and Scholar Rock Holding (NASDAQ: SRRK)
Wedbush Analyst forecast on CH:6C1
Robert Driscoll
Wedbush
Wedbush
CHF8.8
Buy
―
Reiterated
06/04/26
Analysts Offer Insights on Healthcare Companies: Century Therapeutics (NASDAQ: IPSC), Veeva Systems (NYSE: VEEV) and CytomX Therapeutics (NASDAQ: CTMX)
Wolfe Research Analyst forecast on CH:6C1
Kalpit Patel
Wolfe Research
Wolfe Research
CHF4.8
Buy
―
Initiated
05/19/26
CytomX Therapeutics initiated with an Outperform at Wolfe ResearchCytomX Therapeutics initiated with an Outperform at Wolfe Research
H.C. Wainwright Analyst forecast on CH:6C1
Mitchell Kapoor
H.C. Wainwright
H.C. Wainwright
CHF13.6→CHF8.8
Buy
―
Reiterated
05/11/26
CytomX Therapeutics price target lowered to $11 from $17 at H.C. WainwrightCytomX Therapeutics price target lowered to $11 from $17 at H.C. Wainwright
Cantor Fitzgerald Analyst forecast on CH:6C1
Olivia Brayer
Cantor Fitzgerald
Cantor Fitzgerald
CHF8→CHF9.6
Buy
―
Reiterated
03/20/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Jefferies Analyst forecast on CH:6C1
Roger Song
Jefferies
Jefferies
CHF6.4→CHF12.8
Buy
―
Reiterated
03/18/26
CytomX Therapeutics price target raised to $16 from $8 at JefferiesCytomX Therapeutics price target raised to $16 from $8 at Jefferies
Roth MKM Analyst forecast on CH:6C1
Unknown Analyst
Roth MKM
Not Ranked
Roth MKM
CHF2.8
Buy
―
Initiated
09/17/25
CytomX Therapeutics (CTMX) Initiated with a Buy at Roth MKM
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
J.P. Morgan Analyst forecast on CH:6C1
Anupam Rama
J.P. Morgan
J.P. Morgan
CHF8.8
Buy
―
Reiterated
08/17/26
CytomX Therapeutics (CTMX) Gets a Buy from J.P. Morgan
Barclays Analyst forecast on CH:6C1
Etzer Darout
Barclays
Barclays
CHF12.8
Buy
―
Reiterated
08/07/26
Barclays Sticks to Their Buy Rating for CytomX Therapeutics (CTMX)
Guggenheim Analyst forecast on CH:6C1
Michael Schmidt
Guggenheim
Guggenheim
CHF12→CHF11.2
Buy
―
Reiterated
08/07/26
CytomX Therapeutics price target lowered to $14 from $15 at GuggenheimCytomX Therapeutics price target lowered to $14 from $15 at Guggenheim
Piper Sandler Analyst forecast on CH:6C1
Edward Tenthoff
Piper Sandler
Piper Sandler
CHF9.6
Buy
―
Reiterated
08/07/26
Analysts Offer Insights on Healthcare Companies: CytomX Therapeutics (NASDAQ: CTMX), Cytokinetics (NASDAQ: CYTK) and Scholar Rock Holding (NASDAQ: SRRK)
Wedbush Analyst forecast on CH:6C1
Robert Driscoll
Wedbush
Wedbush
CHF8.8
Buy
―
Reiterated
06/04/26
Analysts Offer Insights on Healthcare Companies: Century Therapeutics (NASDAQ: IPSC), Veeva Systems (NYSE: VEEV) and CytomX Therapeutics (NASDAQ: CTMX)
Wolfe Research Analyst forecast on CH:6C1
Kalpit Patel
Wolfe Research
Wolfe Research
CHF4.8
Buy
―
Initiated
05/19/26
CytomX Therapeutics initiated with an Outperform at Wolfe ResearchCytomX Therapeutics initiated with an Outperform at Wolfe Research
H.C. Wainwright Analyst forecast on CH:6C1
Mitchell Kapoor
H.C. Wainwright
H.C. Wainwright
CHF13.6→CHF8.8
Buy
―
Reiterated
05/11/26
CytomX Therapeutics price target lowered to $11 from $17 at H.C. WainwrightCytomX Therapeutics price target lowered to $11 from $17 at H.C. Wainwright
Cantor Fitzgerald Analyst forecast on CH:6C1
Olivia Brayer
Cantor Fitzgerald
Cantor Fitzgerald
CHF8→CHF9.6
Buy
―
Reiterated
03/20/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Jefferies Analyst forecast on CH:6C1
Roger Song
Jefferies
Jefferies
CHF6.4→CHF12.8
Buy
―
Reiterated
03/18/26
CytomX Therapeutics price target raised to $16 from $8 at JefferiesCytomX Therapeutics price target raised to $16 from $8 at Jefferies
Roth MKM Analyst forecast on CH:6C1
Unknown Analyst
Roth MKM
Not Ranked
Roth MKM
CHF2.8
Buy
―
Initiated
09/17/25
CytomX Therapeutics (CTMX) Initiated with a Buy at Roth MKM
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
AVBPArriVent BioPharma, Inc.
BTSGBrightSpring Health Services, Inc.
GPCRStructure Therapeutics, Inc. Sponsored ADR
AMLXAmylyx Pharmaceuticals Inc
IMMXImmix Biopharma
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering CytomX Therapeutics

3 Months
Etzer DaroutBarclays
Success Rate
8/15 ratings generated profit
53%
Average Return
+9.74%
Copying Etzer Darout's trades and holding each position for 3 Months would result in 53.33% of your transactions generating a profit, with an average return of +9.74% per trade.
1 Year
Robert DriscollWedbush
Success Rate
8/15 ratings generated profit
53%
Average Return
+18.68%
Copying Robert Driscoll's trades and holding each position for 1 Year would result in 53.33% of your transactions generating a profit, with an average return of +18.68% per trade.
2 Years
Robert DriscollWedbush
Success Rate
6/15 ratings generated profit
40%
Average Return
+6.36%
Copying Robert Driscoll's trades and holding each position for 2 Years would result in 40.00% of your transactions generating a profit, with an average return of +6.36% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

6C1 Analyst Recommendation Trends

Rating
Apr 26
May 26
Jun 26
Jul 26
Aug 26
Strong Buy
15
19
9
9
6
Buy
0
0
0
0
0
Hold
1
0
1
1
1
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
16
19
10
10
7
In the current month, 6C1 has received 6 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. 6C1 average Analyst price target in the past 3 months is 10.24.
Each month's total comprises the sum of three months' worth of ratings.

6C1 Financial Forecast

6C1 Earnings Forecast

Next quarter’s earnings estimate for 6C1 is -CHF0.06 with a range of -CHF0.09 to CHF0.02. The previous quarter’s EPS was -CHF0.07. 6C1 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year 6C1 has Performed in-line its overall industry.
Next quarter’s earnings estimate for 6C1 is -CHF0.06 with a range of -CHF0.09 to CHF0.02. The previous quarter’s EPS was -CHF0.07. 6C1 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year 6C1 has Performed in-line its overall industry.

6C1 Sales Forecast

Next quarter’s sales forecast for 6C1 is CHF8.48M with a range of CHF1.27M to CHF30.10M. The previous quarter’s sales results were CHF1.15M. 6C1 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year 6C1 has Performed in-line its overall industry.
Next quarter’s sales forecast for 6C1 is CHF8.48M with a range of CHF1.27M to CHF30.10M. The previous quarter’s sales results were CHF1.15M. 6C1 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year 6C1 has Performed in-line its overall industry.

6C1 Stock Forecast FAQ

What is CH:6C1’s average 12-month price target, according to analysts?
Based on analyst ratings, CytomX Therapeutics Inc’s 12-month average price target is 10.24.
    What is CH:6C1’s upside potential, based on the analysts’ average price target?
    Currently there's no upside potential for CH:6C1, based on the analysts’ average price target.
    Can I see which stocks the top-ranking analysts are rating?
    Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
      How can I follow the stock ratings of top Wall Street analysts?
      Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
        Is CytomX Therapeutics Inc a Buy, Sell or Hold?
        CytomX Therapeutics Inc has a consensus rating of Strong Buy, which is based on 5 buy ratings, 0 hold ratings and 0 sell ratings.
          What is CytomX Therapeutics Inc’s share price target?
          The average share price target for CytomX Therapeutics Inc is 10.24. This is based on 5 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
          The highest analyst share price target is CHF12.80 ,and the lowest forecast is CHF8.80. The average share price target represents N/A Increase from the current price of N/A.
            What do analysts say about CytomX Therapeutics Inc?
            CytomX Therapeutics Inc’s analyst rating consensus is a Strong Buy. This is based on the ratings of 5 Wall Streets Analysts.
              How can I buy shares of CytomX Therapeutics Inc?
              To buy shares of CH:6C1, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.